Taj Pharma Opens Chemotherapy Plant in Daman With Rs 100 Cr Investment
The Oncology Plant will cater exclusively to Oncology products. Taj Phamra group is present in over 40 countries and has around 6,000 employees across 15 plants.
Taj Pharmaceuticals India Formulations, a subsidiary of India Drug Company company Taj Pharma Group, has opened its first R&D and pharmaceutical manufacturing facility with an initial investment of Rs 100 crore in Daman. The company plans to produce anti-cancer products oral solid dosage forms, including anti-cancer tablets, anti-cancer capsules, anti-cancer hard gelatin capsules,anti-cancer Liquid Injections and anti-cancer Lyophilized Injections. This would be one stop for 130 oncology products which will cover major type of anti-cancers.
“This is only the first step. We plan to invest more in Oncology Segement,” Taj Pharma Group director Abhishek Singh said on Wednesday.
The group is present in over 40 countries and has around 6,000 employees across 15 plants, 10 R&D centres and 33 affiliated companies, according to the company.
Labels: Mumbai FDA approves chemotherapy drugs unit taj directors Taj Pharmaceuticals cancer drug generic chemotherapy injections generic cancer sold chemotherapy mumbai company granted licence Taj Ahmedabad Taj Pharma Mumbai generic cancer approved USFDA inspection chemotherapy Mumbai news National chemotherapy News India chemotherapy News Breaking chemotherapy News India Today’s national news Latest national news National news headlines News chemotherapy Maharashtra News chemotherapy Mumbai News